{
    "clinical_study": {
        "@rank": "4761", 
        "arm_group": [
            {
                "arm_group_label": "High Dose Protein (Individualized)", 
                "arm_group_type": "Experimental", 
                "description": "Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge"
            }, 
            {
                "arm_group_label": "High Dose Protein (Standardized)", 
                "arm_group_type": "Experimental", 
                "description": "Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge"
            }, 
            {
                "arm_group_label": "Standard protein supplementation", 
                "arm_group_type": "Active Comparator", 
                "description": "Protein supplementation independent of individual breast milk content using a standard dose of a standard breast milk fortifier until 1 week before discharge"
            }
        ], 
        "brief_summary": {
            "textblock": "Although expressed breast milk is considered the optimal nutritional source for preterm\n      infants, the macronutrient content is insufficient to enable optimal growth  during neonatal\n      intensive care. Optimal dose and optimal mode of administration (standardized or\n      individualized) of enteral protein supplementation to very preterm infants have not been\n      established.\n\n      This study aims to compare the effects on weight gain of different modes of enteral protein\n      supplementation."
        }, 
        "brief_title": "Protein for Premies", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Extreme Prematurity", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  very preterm infants <32 weeks gestation and <1500g birth weight\n\n          -  > 100ml/kg/d of enteral feeding\n\n        Exclusion Criteria:\n\n          -  missing informed consent\n\n          -  decision not to feed breast milk\n\n          -  congenital malformations\n\n          -  age > 7 days at study entry"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "7 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773902", 
            "org_study_id": "PfP3.2"
        }, 
        "intervention": [
            {
                "arm_group_label": "High Dose Protein (Individualized)", 
                "description": "Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge", 
                "intervention_name": "High Dose Protein (Individualized)", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "High Dose Protein (Standardized)", 
                "description": "Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge", 
                "intervention_name": "High Dose Protein (Standardized)", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Standard protein supplementation", 
                "description": "Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge", 
                "intervention_name": "Standard Protein Supplementation", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 20, 2013", 
        "location": {
            "contact": {
                "email": "axel.franz@med.uni-tuebingen.de", 
                "last_name": "Axel Franz, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Tuebingen", 
                    "country": "Germany", 
                    "zip": "72076"
                }, 
                "name": "University Children's Hospital Tuebingen"
            }, 
            "investigator": {
                "last_name": "Christoph Maas, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "High Versus Standard Dose Protein for Very Preterm Infants", 
        "other_outcome": {
            "measure": "Plasma amino acid profile", 
            "safety_issue": "Yes", 
            "time_frame": "at 2 and 4 weeks after start of intervention"
        }, 
        "overall_contact": {
            "email": "axel.franz@med.uni-tuebingen.de", 
            "last_name": "Axel Franz, MD"
        }, 
        "overall_official": {
            "affiliation": "University of Tuebingen, Germany", 
            "last_name": "Axel Franz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Weight gain", 
            "safety_issue": "No", 
            "time_frame": "From birth - to the end of study intervention (anticipated to be on average 1 week before discharge home at approx 37 weeks PMA)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773902"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital Tuebingen", 
            "investigator_full_name": "Axel Franz", 
            "investigator_title": "PD Dr. med.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Head circumference growth", 
            "safety_issue": "No", 
            "time_frame": "From birth - to the end of study intervention (anticipated to be on average 1 week before discharge home at approx 37 weeks PMA)"
        }, 
        "source": "University Hospital Tuebingen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital Tuebingen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}